Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Durable moving bed carpet
Contact UsThe vacuum cleaner mobile test bench, model ZYXCQ-8A, is an intelligent aging test bench designed and implemented based on the complete machine testing requirements of the IEC-60312 standard.
-
Deye SUN-8K-G06P3-EU-AM2-P1
Contact Us2 MPP trackers, Max.effciency up to 98.5%
Zero export application,VSG application
String intelligent monitoring (optional)
Wide output voltage range
Anti-PlD function (Optional) -
Paclitaxel for Injection(Albumin-Bound)
Contact UsAlbumin-bound paclitaxel takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility
-
Пластина из нержавеющей стали 08Х18Н10
Contact UsНаиболее важными элементами в 304 являются Ni и Cr, но они не ограничиваются этими двумя элементами.
Reviews
There are no reviews yet.